Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

HHS halts distribution of Lilly’s bamlanivimab/etesevimab antibody cocktail

By Brian Buntz | June 25, 2021

HHS
U.S. government authorities have decided to immediately pause the distribution of Eli Lilly’s bamlanivimab and etesevimab over concerns that the monoclonal antibody cocktail is ineffective against some SARS-CoV-2 variants.

CDC recently concluded that the Gamma variant (P.1) and the Beta variant (B.1.351) make up 11% of COVID-19 infections. They are also continuing to become more dominant, as is the Delta variant (B.1.617.2). CDC has determined that the Delta variant is possibly less responsive to some monoclonal antibody treatments.

The Beta and Gamma variants are significantly less responsive to bamlanivimab and etesevimab than other viral lineages.

bamlanivimab and etesevimab

Bamlanivimab and etesevimab image courtesy of Lilly.

FDA is recommending Regeneron’s REGEN-COV and GSK’s sotrovimab as more robust antibody therapies.

In related news, FDA recently granted emergency use authorization to tocilizumab, a monoclonal antibody from Roche.

In April, FDA had revoked the emergency use authorization for bamlanivimab alone as a COVID-19 treatment, recommending the combination of bamlanivimab and etesevimab instead.

In May, HHS had paused the use of the bamlanivimab/etesevimab cocktail due to surging viral variants in several states.


Filed Under: Infectious Disease, Uncategorized
Tagged With: B.1.351, B.1.617.2, Beta variant, coronavirus, covid-19, Delta variant, Eli Lilly, Eli Lilly & Co., FDA, Gamma variant, investigational monoclonal antibody, monoclonal antibody, P.1, SARS-CoV-2 variants
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Trikafta wins Canadian approval for Trikafta in children with cystic fibrosis
Moderna
Moderna seeks FDA blessing for second COVID-19 vaccine booster
Novartis
Novartis partners with Carisma Therapeutics on manufacturing HER2-targeted CAR-M cell therapy
Medicago and GSK
Medicago and GSK win approval from Health Canada for adjuvanted plant-based COVID-19 vaccine

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50